Why did ALGS outperform in Q2 2024?

The stock price of Aligos Therapeutics (ALGS) experienced a significant decline of 64.29% during Q2 2024. Therefore, it is an overstatement to claim that ALGS outperformed in Q2 2024.

Regarding the decline, it can be attributed to several factors:

1. **Earnings Estimate**: The company's earnings per share (EPS) for Q2 2024 was estimated to be ($0.16), which is a decrease from the previous estimate of ($0.21). This indicates a potential decline in profitability, which could have led to negative sentiment among investors.
2. **Financial Performance**: Aligos Therapeutics reported a revenue of $2.68 million for Q2 2024, which was below the analyst estimate of $3.20 million. Additionally, the company had a negative net margin of 607.03% and a negative return on equity of 116.41%. Such financial performance could have contributed to the decline in stock price.
3. **Industry Dynamics**: The biopharmaceutical industry is highly competitive and sensitive to clinical trial outcomes and regulatory approvals. Any setbacks or delays in these areas can negatively impact investor confidence and stock prices.

In conclusion, Aligos Therapeutics did not outperform in Q2 2024, and its stock price decline was likely a result of a combination of factors including earnings estimate, financial performance, and industry dynamics.

|code|Ticker|Name|Date|Percentage Change|market_code|
|---|---|---|---|---|---|
|ALGS|ALGS.O|Aligos|20240614|-1.5942|186|

|code|Ticker|Name|Date|Pre-Market Percentage Change|market_code|
|---|---|---|---|---|---|
|ALGS|ALGS.O|Aligos|20240614|4.311|186|

|code|Ticker|Name|Date|Post-Market Percentage Change|market_code|
|---|---|---|---|---|---|
|ALGS|ALGS.O|Aligos|20240614|0|186|